TransCode Therapeutics
RNAZ
8 hedge funds and large institutions have $266K invested in TransCode Therapeutics in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
905% more capital invested
Capital invested by funds: $26.4K → $266K (+$239K)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 6 → 8 (+2)
2.94% more ownership
Funds ownership: 0.42% → 3.37% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$49.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$513 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.15K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$55 |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $110K | +$119K | +12,740 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $71.4K | +$49.7K | +5,331 | +180% |
|
|
VCM
3
Vanguard Capital Management
Malvern,
Pennsylvania
| $56.4K | +$61.1K | +6,545 | New |
|
|
VFT
4
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $25.7K | +$27.8K | +2,982 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.96K | -$6.15K | -659 | -74% |
|
|
6
Wells Fargo
San Francisco,
California
| $474 | +$513 | +55 | New |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $103 | +$19 | +2 | +20% |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$55 | -8 | Closed |
|
|
9
Osaic Holdings
Scottsdale,
Arizona
| – | -$20 | -3 | Closed |
|
RNAZ Hedge Fund Activity: Q1 2026 in Review
8 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q1 2026, worth a combined $266K — up 905% from $26.4K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RNAZ positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $119K. The largest seller was Tower Research Capital (TRC), cutting an estimated $6.15K.
- 8 institutional investors held TransCode Therapeutics (RNAZ) as of Q1 2026, up from 6 in Q4 2025.
- Funds reported $266K of TransCode Therapeutics stock for Q1 2026, up 905% quarter-over-quarter.
- 4 funds opened new TransCode Therapeutics positions in Q1 2026 and 2 closed out, a net change of +2 holders.
- The largest TransCode Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $119K added.
- The largest TransCode Therapeutics seller in Q1 2026 was Tower Research Capital (TRC), an estimated $6.15K sold.
Based on aggregated 13F filings for Q1 2026.